{"transactions":[{"id":730915,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:59.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-26-003040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003040/form4.xml","form_type":"4"}},{"id":730914,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:59.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":9375,"derivative":{"exercise_price":14.9,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0000905148-26-003040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003040/form4.xml","form_type":"4"}},{"id":752641,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:02:24.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":850,"price":29.86,"value":25381.0,"ownership":{"direct":true},"balance_after":34003,"source":{"system":"sec-edgar","filing":"0000905148-26-002809","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002809/form4.xml","form_type":"4"}},{"id":894188,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:07.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":18894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":34853,"source":{"system":"sec-edgar","filing":"0000905148-26-000953","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000953/form4.xml","form_type":"4"}},{"id":908101,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:17.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3758,"price":34.62,"value":130101.96,"ownership":{"direct":true},"balance_after":15959,"source":{"system":"sec-edgar","filing":"0000905148-26-000677","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000677/form4.xml","form_type":"4"}},{"id":1038332,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"officer":true,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:26:41.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-25-003349","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003349/form4.xml","form_type":"4"}},{"id":1197500,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"officer":true,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:18.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":9375,"derivative":{"exercise_price":14.9,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0000905148-25-000978","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000978/form4.xml","form_type":"4"}},{"id":1289888,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"officer":true,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-31T23:47:49.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":14788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":14788,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":14788},"source":{"system":"sec-edgar","filing":"0000905148-25-000302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000302/form4.xml","form_type":"4"}},{"id":1289887,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"officer":true,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-31T23:47:49.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":19717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026."}],"balance_after":19717,"source":{"system":"sec-edgar","filing":"0000905148-25-000302","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000302/form4.xml","form_type":"4"}},{"id":1557723,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"officer":true,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-29T20:09:32.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to this option vest on March 11, 2025, and 1/48th of the shares subject to this option vest in substantially equal monthly installments over the thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":187500,"derivative":{"exercise_price":1.49,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000905148-24-001016","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824001016/form4.xml","form_type":"4"}},{"id":1948139,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T17:03:25.000Z","date":"2023-03-16","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023."}],"balance_after":150000,"derivative":{"exercise_price":1.65,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-23-019742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123019742/doc4.xml","form_type":"4"}},{"id":1987944,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-28T18:28:28.000Z","date":"2023-02-25","kind":"exercise","acquired":false,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":37146,"derivative":{"underlying":"Common Stock","underlying_shares":4127},"source":{"system":"sec-edgar","filing":"0001209191-23-013866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013866/doc4.xml","form_type":"4"}},{"id":1987943,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-28T18:28:28.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":2156,"price":1.6812,"value":3624.6672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 2,116 shares sold in the price range of $1.68 to $1.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":48087,"source":{"system":"sec-edgar","filing":"0001209191-23-013866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013866/doc4.xml","form_type":"4"}},{"id":1987942,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-28T18:28:28.000Z","date":"2023-02-25","kind":"exercise","acquired":true,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":50243,"source":{"system":"sec-edgar","filing":"0001209191-23-013866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013866/doc4.xml","form_type":"4"}},{"id":2102733,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-11-29T17:25:29.000Z","date":"2022-11-25","kind":"exercise","acquired":false,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":41273,"derivative":{"underlying":"Common Stock","underlying_shares":4127},"source":{"system":"sec-edgar","filing":"0001209191-22-058974","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058974/doc4.xml","form_type":"4"}},{"id":2102732,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-11-29T17:25:29.000Z","date":"2022-11-28","kind":"sale","acquired":false,"shares":2116,"price":2.7193,"value":5754.0388,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 2,116 shares sold in the price range of $2.68 to $2.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":46116,"source":{"system":"sec-edgar","filing":"0001209191-22-058974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058974/doc4.xml","form_type":"4"}},{"id":2102731,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-11-29T17:25:29.000Z","date":"2022-11-25","kind":"exercise","acquired":true,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":48232,"source":{"system":"sec-edgar","filing":"0001209191-22-058974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058974/doc4.xml","form_type":"4"}},{"id":2172155,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-29T21:18:58.000Z","date":"2022-08-25","kind":"exercise","acquired":false,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":45400,"derivative":{"underlying":"Common Stock","underlying_shares":4127},"source":{"system":"sec-edgar","filing":"0001209191-22-047951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047951/doc4.xml","form_type":"4"}},{"id":2172154,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-08-29T21:18:58.000Z","date":"2022-08-26","kind":"sale","acquired":false,"shares":2190,"price":4.0118,"value":8785.842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 2,190 shares sold in the price range of $4.01 to $4.04 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":44105,"source":{"system":"sec-edgar","filing":"0001209191-22-047951","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047951/doc4.xml","form_type":"4"}},{"id":2172153,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-08-29T21:18:58.000Z","date":"2022-08-25","kind":"exercise","acquired":true,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":46295,"source":{"system":"sec-edgar","filing":"0001209191-22-047951","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047951/doc4.xml","form_type":"4"}},{"id":2254057,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-05-27T17:32:23.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":49527,"derivative":{"underlying":"Common Stock","underlying_shares":4127},"source":{"system":"sec-edgar","filing":"0001209191-22-032670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032670/doc4.xml","form_type":"4"}},{"id":2254056,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-05-27T17:32:23.000Z","date":"2022-05-26","kind":"sale","acquired":false,"shares":2154,"price":1.9011,"value":4094.9694,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 2,154 shares sold in the price range of $1.90 to $1.95 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":42168,"source":{"system":"sec-edgar","filing":"0001209191-22-032670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032670/doc4.xml","form_type":"4"}},{"id":2254055,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-05-27T17:32:23.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":44322,"source":{"system":"sec-edgar","filing":"0001209191-22-032670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032670/doc4.xml","form_type":"4"}},{"id":2325128,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-18T17:34:02.000Z","date":"2022-03-17","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the \"Vesting Commencement Date\"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date."}],"balance_after":150000,"derivative":{"exercise_price":3.04,"expiration_date":"2032-03-17","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-22-020078","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122020078/doc4.xml","form_type":"4"}},{"id":2366403,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-01T21:12:48.000Z","date":"2022-02-25","kind":"exercise","acquired":true,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":53654,"derivative":{"underlying":"Common Stock","underlying_shares":4127},"source":{"system":"sec-edgar","filing":"0001209191-22-014441","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014441/doc4.xml","form_type":"4"}},{"id":2366402,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-01T21:12:48.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":2395,"price":2.7795,"value":6656.9025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 2,395 shares sold in the price range of $2.7101 to $2.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":40195,"source":{"system":"sec-edgar","filing":"0001209191-22-014441","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014441/doc4.xml","form_type":"4"}},{"id":2366401,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-01T21:12:48.000Z","date":"2022-02-25","kind":"exercise","acquired":true,"shares":4127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":42590,"source":{"system":"sec-edgar","filing":"0001209191-22-014441","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014441/doc4.xml","form_type":"4"}},{"id":2493564,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2021-11-29T19:50:19.000Z","date":"2021-11-25","kind":"exercise","acquired":false,"shares":8254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":57781,"derivative":{"underlying":"Common Stock","underlying_shares":8254},"source":{"system":"sec-edgar","filing":"0001209191-21-067046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067046/doc4.xml","form_type":"4"}},{"id":2493563,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-29T19:50:19.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":2591,"price":4.8191,"value":12486.2881,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 2,591 shares sold in the price range of $4.62 to $5.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":38463,"source":{"system":"sec-edgar","filing":"0001209191-21-067046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067046/doc4.xml","form_type":"4"}},{"id":2493562,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-29T19:50:19.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":1950,"price":4.8006,"value":9361.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 1,950 shares sold in the price range of $4.7150 to $5.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":41054,"source":{"system":"sec-edgar","filing":"0001209191-21-067046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067046/doc4.xml","form_type":"4"}},{"id":2493561,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-29T19:50:19.000Z","date":"2021-11-25","kind":"exercise","acquired":true,"shares":8254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":43004,"source":{"system":"sec-edgar","filing":"0001209191-21-067046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067046/doc4.xml","form_type":"4"}},{"id":2714979,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T17:46:03.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":2061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One forty-eighth (1/48th ) of the Shares subject to the Option shall vest on February 28, 2021, and one forty-eighth (1/48th ) of the total Shares subject to the Option shall vest each month thereafter on the last day of such month, subject to the reporting person continuing to be a Service Provider (as defined in the Plan) through each such date."}],"balance_after":30956,"derivative":{"exercise_price":3.58,"expiration_date":"2031-01-08","underlying":"Common Stock","underlying_shares":2061},"source":{"system":"sec-edgar","filing":"0001209191-21-032413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121032413/doc4.xml","form_type":"4"}},{"id":2714978,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T17:46:03.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":32689,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of May 1, 2020 (the \"Vesting Commencement Date\"), and one forty-eighth (1/48th ) of the total shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through each such date."}],"balance_after":98069,"derivative":{"exercise_price":1.26,"expiration_date":"2030-07-08","underlying":"Common Stock","underlying_shares":32689},"source":{"system":"sec-edgar","filing":"0001209191-21-032413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121032413/doc4.xml","form_type":"4"}},{"id":2714977,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-13T17:46:03.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":2061,"price":3.58,"value":7378.38,"ownership":{"direct":true},"balance_after":34750,"source":{"system":"sec-edgar","filing":"0001209191-21-032413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121032413/doc4.xml","form_type":"4"}},{"id":2714976,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-13T17:46:03.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":32689,"price":1.26,"value":41188.14,"ownership":{"direct":true},"balance_after":32689,"source":{"system":"sec-edgar","filing":"0001209191-21-032413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121032413/doc4.xml","form_type":"4"}},{"id":2768374,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":36478,"kind":"person","name":"Rojkjaer Lisa","position":1,"cik":"0001846460","reported_name":"Rojkjaer Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T20:28:38.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":126890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 26, 2021 (the \"Vesting Commencement Date\"), and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date."}],"balance_after":126890,"derivative":{"exercise_price":8.74,"expiration_date":"2031-03-26","underlying":"Common Stock","underlying_shares":126890},"source":{"system":"sec-edgar","filing":"0001209191-21-023669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121023669/doc4.xml","form_type":"4"}}]}